TickerFacts.

Company research / XENE

Xenon Pharmaceuticals Inc. (XENE)

Build a valuation ↗↓ Download CSV

CIK 0001582313 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Xenon Pharmaceuticals Inc. reported revenue of $7.50M. Over the twelve months to 2026-06-30, revenue was $0.

Key ratios (year ended 2025-12-31)

n/m
Operating margin
n/m
Net margin
-59.5%
Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-16

Headquarters locality: Burnaby · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$0$7.50M$0$0$9.43M$18.44M$32.17M$6.83Mn/an/an/a
R&D Expense$352.49M$300.94M$210.39M$167.51M$105.77M$75.46M$50.52M$38.84M$23.63M$25.57M$19.83M
Operating Income-$441.59M-$373.07M-$279.30M-$214.05M-$129.14M-$78.99M-$31.30M-$42.82M-$38.04M-$32.58M-$24.82M
Depreciation & Amortization$2.40M$2.54M$2.56M$2.06M$1.41M$906.0K$644.0K$429.0K$586.0K$649.0K$864.0K
EBITDA-$439.19M-$370.53M-$276.74M-$211.99M-$127.74M-$78.09M-$30.66M-$42.39M-$37.45M-$31.93M-$23.95M
Net Income-$409.19M-$345.91M-$234.33M-$182.39M-$125.37M-$78.88M-$28.84M-$41.59M-$34.50M-$30.70M-$23.00M
EPS (Diluted)n/a-$4.36-$3.01-$2.73-$2.06-$1.77-$0.81n/a-$1.63-$1.72-$1.48
Total Assets$1.30B$633.16M$798.14M$964.80M$754.15M$572.01M$189.19M$147.70M$122.43M$46.12M$67.49M
Total Liabilities$53.38M$51.40M$43.24M$36.88M$32.65M$21.97M$17.83M$55.72M$19.13M$10.19M$3.59M
Shareholders' Equity$1.24B$581.76M$754.90M$927.92M$721.50M$550.03M$171.35M$91.98M$103.30M$35.93M$63.90M
Cash & Equivalents$119.53M$199.16M$142.71M$148.64M$57.24M$175.69M$45.01M$24.75M$67.75M$20.49M$17.09M
Operating Cash Flow-$337.52M-$279.12M-$181.39M-$151.11M-$101.03M-$69.50M-$48.12M-$4.71M-$34.72M-$28.73M-$19.57M
Capital Expenditures$1.01M$799.0K$3.08M$5.62M$2.89M$2.05M$2.64M$1.24M$507.0K$315.0K$279.0K
Free Cash Flow-$338.53M-$279.92M-$184.46M-$156.73M-$103.92M-$71.55M-$50.76M-$5.95M-$35.23M-$29.04M-$19.85M
Shares Outstanding96.75M80.01M76.42M75.37M62.59M51.63M35.01M28.14M25.75M18.00M17.93M
Weighted Average Diluted Sharesn/a79.25M77.89M66.89M60.54M43.63M34.54Mn/a19.43M18.00M15.49M
EPS (Basic)n/a-$4.36-$3.01-$2.73-$2.06-$1.77-$0.81n/a-$1.63-$1.71-$1.48

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView